PharmaShots | Incisive News in 3 Shots

Subscribe Now

idecabtagene vicleucel

$BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma$

BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma

August 20, 2021

BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma

BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma

September 23, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us